Pilot study tests cell therapy for difficult-to-heal diabetic foot ulcers

Researchers at the Wake Forest Institute for Regenerative Medicine have successfully tested an experimental placental stem cell therapy on 10 patients with chronic diabetic foot ulcers. All participants achieved complete wound closure within six months, with no serious adverse events reported during the 12-month follow-up.
Why it matters
Diabetic foot ulcers are a leading cause of lower-limb amputations, and this therapy offers a potential breakthrough for patients with limited treatment options for nerve damage and wound healing.
by Wake Forest University School of Medicine
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Graphical Abstract. Credit: Stem Cells Translational Medicine (2026). DOI: 10.1093/stcltm/szag085 An experimental cell therapy was well tolerated in 10 people with chronic diabetic foot ulcers, according to a first-in-human study led by researchers at Wake Forest Institute for Regenerative Medicine (WFIRM).
All 10 participants experienced complete wound closure within six months, and tests indicated improved sensation in the treated feet during the 12-month follow-up period. These encouraging findings support further investigation. The findings were published in Stem Cells Translational Medicine .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in